• Colorcon Ventures Invests in i20 Therapeutics contractpharma
    December 08, 2020
    ​i2O Therapeutics, a biotech company developing a platform to enable oral delivery of traditionally injectable biological drugs, has received a strategic investment from Colorcon Ventures, the corporate venture fund of Colorcon Inc.
PharmaSources Customer Service